Xagenic Appoints Seasoned Industry Veteran Randall Wilhoite As Vice President Of Operations

TORONTO--(BUSINESS WIRE)--Xagenic, a molecular diagnostics company developing the Xagenic X1™ platform for use at the point of care, today announced that Randall Wilhoite has joined the Company as Vice President of Operations. Wilhoite will oversee manufacturing and operations to ensure the company's commercial objectives for the Xagenic X1 platform are met.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.